wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38598277-5C4C5CEE-EC28-46DF-8446-0BC209D4D198
Q38598277-5C4C5CEE-EC28-46DF-8446-0BC209D4D198
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38598277-5C4C5CEE-EC28-46DF-8446-0BC209D4D198
Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?
P2860
Q38598277-5C4C5CEE-EC28-46DF-8446-0BC209D4D198
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38598277-5C4C5CEE-EC28-46DF-8446-0BC209D4D198
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
63798642f93a4333a00e59eb22cb525cb9129b55
P2860
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).